CAMP
CalAmp Corp.CAMP
CAMP
Delisted
CAMP was delisted on the 11th of June, 2024.
About: CalAmp Corp provides wireless communications solutions applications to customers. The company's products, software, and application services are sold into a broad array of market verticals, including transportation, government, construction, and automotive to customers in the United States; Latin America; Europe the Middle East, and Africa; Asia-Pacific; and others. Its business activities are organized into its Telematics Systems and Software & Subscription Services. The Telematics Systems segment offers a series of Mobile Resource Management ('MRM') telematics products and applications. The software & Subscription Services segment offers cloud-based application enablement and telematics service platforms.
Employees: 644
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes
Neutral
GlobeNewsWire
2 weeks ago
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.
Neutral
GlobeNewsWire
1 month ago
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression
Positive
Benzinga
1 month ago
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
GlobeNewsWire
2 months ago
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025
Neutral
GlobeNewsWire
2 months ago
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D.
Neutral
GlobeNewsWire
2 months ago
CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
Neutral
GlobeNewsWire
2 months ago
CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
Neutral
GlobeNewsWire
3 months ago
CAMP4 to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
4 months ago
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today provided corporate updates and key objectives for 2025.
Charts implemented using Lightweight Charts™